OR (95% CI) for stroke according to CHA2DS2-VASc score, indexed left atrial size and atrial fibrillation combined: the Tromsø Study 1994–2012
| Model 1 | Model 2 | |
|---|---|---|
| CHA2DS2-VASc and LA size | ||
| CHA2DS2-VASc=0, Group 1 (n=957) | 1 (Ref.) | 1 (Ref.) |
| CHA2DS2-VASc ≥1 | ||
| LA size <2.8, Group 2 (n=1713) | 3.9 (2.7 to 5.5) | 3.7 (2.6 to 5.3) |
| LA size ≥2.8, Group 3 (n=96) | 9.7 (5.6 to 16.7) | 9.4 (5.3 to 16.4) |
| Atrial fibrillation (AF)* | ||
| No AF, Group 1 (n=2391) | 1 (Ref.) | 1 (Ref.) |
| Late AF, Group 2 (n=266) | 1.0 (0.7 to 1.6) | 1.0 (0.6 to 1.5) |
| Early AF, Group 3 (n=142) | 2.8 (1.9 to 4.2) | 2.6 (1.7 to 3.9) |
| Previous AF, Group 4 (n=45) | 2.4 (1.2 to 5.0) | 2.2 (1.1 to 4.5) |
| Combined analytical group | ||
| CHA2DS2-VASc=0, Group 1 (n=957) | 1 (Ref.) | 1 (Ref.) |
| CHA2DS2-VASc ≥1 and LA size <2.8 | ||
| AF, Group 2 (n=331) | 5.0 (3.3 to 7.7) | 4.9 (3.1 to 7.6) |
| No AF, Group 3 (n=1382) | 3.6 (2.5 to 5.1) | 3.5 (2.4 to 5.0) |
| CHA2DS2-VASc ≥1 and LA size ≥2.8 | ||
| AF, Group 4 (n=43) | 7.1 (3.3 to 15.5) | 6.3 (2.8 to 14.3) |
| No AF, Group 5 (n=53) | 12.1 (6.3 to 23.2) | 12.5 (6.4 to 24.3) |
| Smoking (no/yes) | 1.1 (0.8 to 1.4) | |
| Total/HDL cholesterol ratio | 1.1 (1.1 to 1.2) | |
| BMI (kg/m2) | 1.1 (1.02 to 1.1) | |
| GFR <60 mL/min/1.73 m² | 2.6 (1.3 to 5.5) | |
Model 1: Unadjusted.
Model 2: Adjusted for smoking, Total/HDL cholesterol ratio, BMI, GFR.
*AF, any diagnosis of AF before or until up to date of stroke; early AF, AF diagnosed from 1994 to 2002; Late AF, AF diagnosed from 2003 to 2012; previous AF, AF at baseline.